This paper describes the cohort, along with the data and bio-samples available for future studies in PCa risk assessment.<h4>Participants</h4>Canadian men at risk of PCa were enrolled based on one of two criteria (1) negative first prostate biopsy within 6 months from enrolment (Group 1); or (2) a prostate-specific antigen (PSA) blood level between 2.5 and 10 ng/mL without prior prostate biopsy (Group 2). The gene discussed is KLK3; the disease is posterior cortical atrophy.